Singapore markets open in 8 hours 14 minutes

LLY Jan 2024 210.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.09000.0000 (0.00%)
As of 12:18PM EDT. Market open.
Full screen
Previous close0.0900
Expiry date2024-01-19
Day's range0.0800 - 0.0900
Contract rangeN/A
Open interest835
  • Financial Times

    Eli Lilly to buy cancer specialist Point for $1.4bn

    Eli Lilly, the world’s largest drugmaker, plans to bolster its portfolio of cancer drugs by buying Point Biopharma for $1.4bn, paying a premium of almost 90 per cent to Monday’s closing price. The Indianapolis-based pharma group has become the second major drugmaker after Swiss company Novartis to invest in radioligand therapy, which involves molecules delivering radiation at close range to cancerous cells and is more targeted than radiotherapy. Jacob Van Naarden, president of the company’s oncology division Loxo@Lilly, said the acquisition of Point would be the “beginning of our investment in developing multiple meaningful radioligand medicines for hard-to-treat cancers”.

  • Zacks

    Why Investors Need to Take Advantage of These 2 Medical Stocks Now

    Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

  • Zacks

    Lilly's (LLY) Eczema Candidate Lebrikizumab Faces FDA Rejection

    Lilly (LLY) gets a CRL for the eczema candidate, lebrikizumab, based on inspection findings at a third-party manufacturer.